Seizure-Busting Rally and Cancer Shockwaves— These Stocks Are Heating Up into the Close

September 8, 2025

DENVER, Colo., Sep 08, 2025 (247marketnews.com)- As markets head into the final stretch of today’s session, all eyes are on a select group of stocks delivering outsized moves on game-changing clinical trial updates and growing institutional interest. These names are lighting up watchlists for the close and after-hours session.

Rapport Therapeutics (NASDAQ:RAPP) is commanding Wall Street’s attention today after reporting positive topline results from its Phase 2a trial for RAP-219, a first-in-class therapy targeting drug-resistant focal onset seizures. The data speaks volumes:

  • 77.8% reduction in clinical seizures (p=0.01)
  • 24% of patients achieved complete seizure freedom (p<0.0001)

Dr. Jacqueline French of NYU Langone called it “the first time a novel antiseizure medication was evaluated using an objective biomarker of seizure activity.” With a Phase 3 registrational trial now in sight for 2026, the biotech is breaking out. Expect continued interest in after-hours trading as institutional buyers circle, but keep an eye on a potential funding deal.

Lixte Biotechnology (NASDAQ:LIXT) is surging after momentum builds around LB-100, its lead PP2A inhibitor dubbed a “cancer power-up” by oncologists. The drug is drawing attention for its ability to force tumors into lethal activation while supercharging chemo and immunotherapy response.

Currently in trials for ovarian clear-cell carcinoma with GlaxoSmithKline (NYSE:GSK), LB-100 is positioned as a potential paradigm shift in immuno-oncology, with synergy noted in immune checkpoint blockade and tumor microenvironment remodeling. Watch for conference updates or data drops in the coming weeks.

Sentage Holdings (NASDAQ:SNTG) is seeing speculative flows late in the session, despite no fresh company-specific news. Known for past parabolic intraday spikes, the stock is likely riding sympathy momentum from other micro-cap runners. Traders are eyeing key resistance at $1.25, where a breakout could trigger after-hours algo interest.

Microbot Medical (NASDAQ:MBOT) is quietly building steam ahead of expected updates on its Self-Cleaning Shunt (SCS) system, designed to reduce device occlusions in brain and spinal procedures. With recent mentions in surgical device symposiums and a history of low-float volatility, MBOT is one of the under-the-radar movers on today’s biotech sweep.

Acrivon Therapeutics (NASDAQ:ACRV) is rebounding off a multi-month low, riding optimism around its precision oncology pipeline, including ACR-368, a selective CHK1/2 inhibitor. The stock appears to be accumulated ahead of expected Q4 pipeline updates.

Dianthus Therapeutics (NASDAQ:DNTH) is catching a bid amid chatter about possible upcoming catalysts in its monoclonal antibody programs targeting complement-mediated diseases. While the company has kept a low profile since its IPO, speculative biotech investors are looking for low-float names with immune disease exposure.

Power Hour Takeaway

Today’s action reflects a clear appetite for asymmetric risk, particularly in small-cap biotech and speculative healthcare names. Rapport’s seizure data is the clear market mover, while LIXT is building a longer-term thesis around tumor microenvironment manipulation.

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 247 is a third-party media provider and has been compensated by one or more featured companies. Please review our Full Disclaimer https://www.247marketnews.com/disclaimer/. Please go to https://247marketnews.com/lixte-biotechnology/ for further LIXT and 247marketnews.com disclosure information. 247 has been paid by Microcap Advisory for providing ongoing LIXT market outreach and other services.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (LIXT, OCTO, PL, QS, RAPP, HOUR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.